Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line

Clinical evidence regarding eribulin treatment for patients with soft tissue sarcoma (STS) is limited to those with L-sarcoma (leiomyosarcoma and liposarcoma) who have completed at least two chemotherapies. Whether histological subtypes and treatment lines affect the efficacy and safety of eribulin...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Clin Oncol
Päätekijät: Nakano, Kenji, Hayakawa, Keiko, Funauchi, Yuki, Tanizawa, Taisuke, Ae, Keisuke, Matsumoto, Seiichi, Tomomatsu, Junichi, Ono, Makiko, Taira, Shinichiro, Nishizawa, Masatoshi, Wang, Xiaofei, Ohmoto, Akihiro, Sato, Yasuyoshi, Fukuda, Naoki, Urasaki, Tetsuya, Takahashi, Shunji
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: D.A. Spandidos 2021
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709564/
https://ncbi.nlm.nih.gov/pubmed/33282288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2175
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia